TriangleFOR PATIENTS · SOURCE READING
Targeted therapy for HER2-positive breast cancer
Source: Targeted Therapy for Breast Cancer, National Cancer Institute.
Source updated: Not stated in this source · Captured 2026-09-09.
Selected source text with whitespace normalised. This Triangle page is not an NCI PDQ summary. Independent clinical review is pending.
NCI patient treatment article for this disease Exact source article; not a clinically reviewed indication or current-standard recommendation.
Context: Targeted Therapy for Breast Cancer
Targeted therapy for HER2-positive breast cancer
HER2 is a protein that helps control breast cell growth. Some breast cancers have too much HER2, which causes the breast cells to grow and divide faster than normal. This is called HER2-positive breast cancer.
Several targeted therapy drugs may be used alone or with other kinds of drugs for HER2-positive breast cancer:
lapatinib
Source links and citations
margetuximab
Source links and citations
neratinib
Source links and citations
pertuzumab
Source links and citations
pertuzumab, trastuzumab, and hyaluronidase-zzxf
Source links and citations
tucatinib
Source links and citations
trastuzumab
Source links and citations
trastuzumab and hyaluronidase-oysk
Source links and citations
trastuzumab deruxtecan
Source links and citations
Some of these targeted therapy drugs, such as trastuzumab and trastuzumab deruxtecan, may also be used for HER-low breast cancer. HER2-low breast cancers have a small amount of HER2 protein on their surface.
Preserved source evidence · Independent clinical review pending · Not medical advice